Barrett’s-related esophageal adenocarcinoma: Is chemoprevention a potential option?

American Journal of Gastroenterology

Volumn 96, Issue 8, 2001, Pages 2302-2305

  Fennerty, M Brian ^a,b,c   Triadafilopoulos, George ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; DRUG EFFECT; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; HUMAN; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMANS;

EID: 0034887528     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02596-5     Document Type: Review

References (40)

1. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
2. Adenocarcinoma of the esophagus and Barrett’s esophagus: A population-based study
3. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
4. Barrett’s esophagus. What do we really know about this disease?
5. Prevalence and clinical spectrum of gastroesophageal reflux. A population-based study in Olmstead County, Minnesota
6. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease
7. Practice guidelines on the diagnosis, surveillance and therapy of Barrett’s esophagus
8. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma
9. Barrett’s esophagus: A new look at surveillance based on emerging estimates of cancer risk
10. Regression of Barrett’s esophagus by laser ablation in an anacid environment
11. Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium
12. Reversal of Barrett’s esophagus with acid suppression and multipolar electrocoagulation: Preliminary results
13. The efficacy and safety of argon plasma coagulation therapy in Barrett’s esophagus
14. Photodynamic therapy for Barrett’s esophagus: Follow-up in 100 patients
15. Perspectives on endoscopic eradication of Barrett’s esophagus. Who are appropriate candidates and what is the best method?
16. Squamous islands in Barrett’s esophagus: What lies underneath?
17. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s esophagus
18. Effect of up to 3 years of high-dose lansoprazole on Barrett’ s esophagus
19. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus
20. Effects of anti-reflux therapy on the extent of Barrett’s epithelium
21. Conservative treatment versus antireflux surgery in Barrett’s oesophagus. Long-term results of a prospective study
22. Barrett’s esophagus. Does an antireflux procedure reduce the need for endoscopic surveillance?
23. Dynamic effects of acid on Barrett’s esophagus
24. Differentiation, and proliferation in Barrett’s esophagus and the effects of acid suppression
25. Aspirin use and risk of fatal cancer
26. Aspirin and reduced risk of esophageal carcinoma
27. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
28. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
29. Induction by cyclooxygenase-2 by activated H-ras oncogene in rat-1 fibroblasts and the role of mitogen activated protein kinase pathway
30. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
31. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas
32. Cyclooxygenase-2 expression in human esophageal carcinoma
33. Cyclooxygenase 2 expression in Barrett’s esophagus, and adenocarcinoma. Ex vivo induction by bile salts and acid exposure
34. Expression of cyclooxygenase 2 (COX-2) in Barrett’s esophagus, dysplasia, and adenocarcinoma
35. Selective inhibition of cyclooxygenase-2 inhibits growth, and induces apoptosis in human esophageal adenocarcinoma cells
36. Chemopreventive potential of selective cyclooxygenase-2 (Cox-2) inhibition in Barrett’s epithelium: An in vitro study
37. Can cyclooxygenase-2 inhibitors prevent cancer in an animal model of Barrett’s esophagus? A randomized, placebo-controlled chemoprevention trial
38. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
39. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
40. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis